Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in December 2013 and is headquartered in Norwood, MA.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRBP
Previous Symbol
CUSIPN/A
Phone617-963-0100
Debt
Debt-to-Equity RatioN/A
Current Ratio3.45
Quick Ratio3.45
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.44 million
Price / Sales152.72
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.04 per share
Price / Book6.26
Profitability
EPS (Most Recent Fiscal Year)($0.65)
Net Income$-32,420,000.00
Net MarginsN/A
Return on Equity-88.53%
Return on Assets-71.21%
Miscellaneous
Employees47
Outstanding Shares57,240,000
Market Cap$372.61 million
OptionableOptionable
Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions
What is Corbus Pharmaceuticals' stock symbol?
Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."
How were Corbus Pharmaceuticals' earnings last quarter?
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) issued its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.05. The biopharmaceutical company had revenue of $1.09 million for the quarter, compared to analysts' expectations of $1.66 million. View Corbus Pharmaceuticals' Earnings History.
When is Corbus Pharmaceuticals' next earnings date?
What price target have analysts set for CRBP?
5 brokers have issued twelve-month price targets for Corbus Pharmaceuticals' stock. Their forecasts range from $22.00 to $36.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $26.25 in the next twelve months. This suggests a possible upside of 303.2% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.
What is the consensus analysts' recommendation for Corbus Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.
Has Corbus Pharmaceuticals been receiving favorable news coverage?
News coverage about CRBP stock has been trending somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are some of Corbus Pharmaceuticals' key competitors?
Some companies that are related to Corbus Pharmaceuticals include Theravance Biopharma (TBPH), Wave Life Sciences (WVE), Enanta Pharmaceuticals (ENTA), The Medicines (MDCO), Cambrex (CBM), Vanda Pharmaceuticals (VNDA), Zai Lab (ZLAB), Tricida (TCDA), Aimmune Therapeutics (AIMT), Phibro Animal Health (PAHC), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Nabriva Therapeutics (NBRV), Esperion Therapeutics (ESPR) and Portola Pharmaceuticals (PTLA).
Who are Corbus Pharmaceuticals' key executives?
Corbus Pharmaceuticals' management team includes the folowing people:
- Yuval Cohen, Chief Executive Officer & Director
- Mark A. Tepper, President & Chief Scientific Officer
- Sean F. Moran, CFO & Principal Accounting Officer
- Barbara White, Chief Medical Officer
- Robert Discordia, VP-Pharmaceutical Development & Manufacturing
Who are Corbus Pharmaceuticals' major shareholders?
Corbus Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.12%), Vanguard Group Inc (4.18%), Vanguard Group Inc. (4.18%), FMR LLC (3.89%), Morgan Stanley (1.54%) and Fuller & Thaler Asset Management Inc. (0.46%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.
Which major investors are selling Corbus Pharmaceuticals stock?
Which major investors are buying Corbus Pharmaceuticals stock?
CRBP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Fuller & Thaler Asset Management Inc., Morgan Stanley, Bridgeway Capital Management Inc., Trexquant Investment LP, Woodstock Corp, Alliancebernstein L.P. and D.A. Davidson & CO.. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.
How do I buy shares of Corbus Pharmaceuticals?
Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corbus Pharmaceuticals' stock price today?
One share of CRBP stock can currently be purchased for approximately $6.51.
How big of a company is Corbus Pharmaceuticals?
Corbus Pharmaceuticals has a market capitalization of $372.61 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe.
What is Corbus Pharmaceuticals' official website?
How can I contact Corbus Pharmaceuticals?
Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]
MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
